What mutations have been reported in hereditary spherocytosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 13, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Mutations Reported in Hereditary Spherocytosis

Hereditary spherocytosis results from mutations in five genes encoding red blood cell membrane proteins: ANK1 (ankyrin-1), SPTB (beta-spectrin), SPTA1 (alpha-spectrin), SLC4A1 (band 3/anion exchanger 1), and EPB42 (protein 4.2), with ANK1 and SPTB mutations accounting for approximately 88% of cases in Chinese populations. 1

Gene-Specific Mutation Patterns

ANK1 (Ankyrin-1) Mutations

  • Nonsense mutations account for approximately 36% (26/73) of ANK1 mutations 1
  • Frameshift mutations represent approximately 27% (20/73) of ANK1 mutations 1
  • Hotspot exons include exons 8,9,26, and 28 where mutations cluster 1
  • ANK1 mutations account for approximately 46% of Chinese HS cases 1
  • Mutations in the ANK1 death domain are associated with lower MCV and MCH levels compared to mutations in other ANK1 domains 2
  • Inheritance is typically autosomal dominant (75%), though recessive cases occur 3

SPTB (Beta-Spectrin) Mutations

  • Nonsense mutations are the most common type, representing approximately 48% (32/66) of SPTB mutations 1
  • Frameshift mutations account for approximately 23% (15/66) of SPTB mutations 1
  • Six frameshift and nonsense mutations have been documented to cause loss of heterozygosity at the cDNA level, reflecting absence of mutant mRNA transcripts 4
  • Hotspot exons include exons 13,15, and 18-30 1
  • SPTB mutations account for approximately 42% of Chinese HS cases 1
  • Most mutations result in a mild to moderate autosomal dominant phenotype with conspicuous spherocytosis and 8-15% acanthocytes 4

SPTA1 (Alpha-Spectrin) Mutations

  • SPTA1 mutations are rare, accounting for only approximately 1% of Chinese HS cases 1
  • Recessive HS commonly results from compound heterozygosity involving a low expression allele paired with a missense mutation 5
  • Defects often involve the promoter or 5'-untranslated region combined with missense mutations 5

SLC4A1 (Band 3) Mutations

  • Missense mutations predominate, accounting for approximately 78% (14/18) of SLC4A1 mutations 1
  • Mutations are scattered throughout the entire gene region without clear hotspots 1
  • SLC4A1 mutations account for approximately 11% of Chinese HS cases 1
  • Inheritance pattern is typically autosomal dominant 5

EPB42 (Protein 4.2) Mutations

  • EPB42 mutations are extremely rare in Chinese populations, with no reported cases in comprehensive reviews 1
  • When present, recessive HS results from compound heterozygosity of various mutations 5

Inheritance Patterns and Novel Findings

  • Approximately 75% of HS cases follow autosomal dominant inheritance 3
  • De novo mutations account for a significant proportion, with 6 out of 13 families in one study showing spontaneous mutations 2
  • Variable expressivity has been documented even in identical twins carrying the same ANK1 c.341C>T variant 2
  • Nearly every family has a unique mutation, with no single frequent defect identified 5

Molecular Consequences

  • Most mutations result in no abnormal protein being present in red cells, as frameshift and nonsense mutations lead to mRNA degradation 5
  • Defects disrupt vertical interactions between the membrane skeleton and lipid bilayer, causing loss of red cell surface area and spheroidal shape 3
  • Rare missense mutations like ankyrin Walsrode (V463I) and beta-spectrin Kissimmee (W202R) have provided insight into functional protein domains 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.